Enterprise Value
1.409B
Cash
681.5M
Avg Qtr Burn
N/A
Short % of Float
10.76%
Insider Ownership
0.23%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MVC-COV1901 Details COVID-19 Vaccine | Approved Update | |
COVID-19 S-Trimer (with Clover Biopharmaceuticals) Details Infectious disease, COVID-19 | Approved Quarterly sales | |
CpG 1018 Details COVID-19 | Approved Quarterly sales | |
Heplisav-B Details Infectious disease, Hepatitis B vaccine, Hepatitis B | Approved Quarterly sales | |
Heplisav-B Details Infectious disease, Hepatitis B vaccine, Hepatitis B | PDUFA Approval decision | |
Phase 2 Data readout | ||
Tdap-1018 (adjuvanted w/ CpG 1018) Details Infectious disease, Tetanus, diphtheria, and pertussis | Phase 2 Initiation | |
Z-1018 (adjuvanted w/ CpG 1018) Details Shingles, Infectious disease, Viral infection | Phase 1/2 Initiation | |
VLA2001 Details Infectious disease, COVID-19 | Failed Discontinued |